p53

PMV’s ASCO data show signs of drugging ‘undruggable’ p53 protein across tumor types

PMV Pharmaceuticals has its first clinical data showing that its lead therapeutic candidate can hit p53, a tumor-suppressing protein long thought to be undruggable. After reporting the preliminary data during ASCO, PMV said it plans to continue the Phase 1 study with the goal of advancing to Phase 2 early next year.

By Frank Vinluan

Pharma, Startups

PMV Pharma gets $74M boost for personalized chemistry

P53: "The guardian of the genome." It's not an HBO series, it's a transcription factor implicated in over 50 percent of human cancers. An attractive target, to say the least, which has helped rally a $74M Series B for New Jersey-based PMV Pharma.

By Juliet Preston